PFE - What's Going On With Pfizer On Thursday? Pharma Giant's Shares Tick Lower | Benzinga
Pfizer Inc. (NYSE:PFE) shares are ticking lower after the company disclosed disappointing results from its Phase 3 CIFFREO study, evaluating the investigational gene therapy for Duchenne muscular dystrophy (DMD) in young boys.
The study did not achieve its primary endpoint of improving motor function in patients aged 4 to 7 years.
The multinational, placebo-controlled trial assessed the efficacy of the gene therapy using the North Star Ambulatory Assessment (NSAA) over one year.
Also Read: Pfizer Highlights ‘Unprecedented’ 5 Year Data From Cancer Drug In Rare Form Of Advanced Lung Cancer
Despite high hopes, ...